Related Experiment Video
Updated: Feb 10, 2026

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
Sequential analysis as a tool for detection of amikacin ototoxicity in the treatment of multidrug-resistant
Karla Anacleto de Vasconcelos1, Silvana Maria Monte Coelho Frota2, Antonio Ruffino-Netto3
1Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Objective:
To investigate early detection of amikacin-induced ototoxicity in a population treated for multidrug-resistant tuberculosis (MDR-TB), by means of three different tests: pure-tone audiometry (PTA); high-frequency audiometry (HFA); and distortion-product otoacoustic emission (DPOAE) testing.
Methods:
This was a longitudinal prospective cohort study involving patients aged 18-69 years with a diagnosis of MDR-TB who had to receive amikacin for six months as part of their antituberculosis drug regimen for the first time. Hearing was assessed before treatment initiation and at two and six months after treatment initiation. Sequential statistics were used to analyze the results.
Results:
We included 61 patients, but the final population consisted of 10 patients (7 men and 3 women) because of sequential analysis. Comparison of the test results obtained at two and six months after treatment initiation with those obtained at baseline revealed that HFA at two months and PTA at six months detected hearing threshold shifts consistent with ototoxicity. However, DPOAE testing did not detect such shifts.
Conclusions:
The statistical method used in this study makes it possible to conclude that, over the six-month period, amikacin-associated hearing threshold shifts were detected by HFA and PTA, and that DPOAE testing was not efficient in detecting such shifts.
Insights
High-frequency audiometry (HFA) and pure-tone audiometry (PTA) effectively detect amikacin-induced ototoxicity in multidrug-resistant tuberculosis (MDR-TB) patients. Distortion-product otoacoustic emission (DPOAE) testing was less efficient for early hearing loss detection.
Area of Science:
- Ototoxicity research
- Audiology
- Tuberculosis treatment monitoring
Background:
- Amikacin is crucial for multidrug-resistant tuberculosis (MDR-TB) treatment.
- Amikacin can cause ototoxicity, leading to hearing loss.
- Early detection of hearing damage is vital for patient management.
Purpose of the Study:
- To evaluate early detection of amikacin-induced ototoxicity.
- To compare pure-tone audiometry (PTA), high-frequency audiometry (HFA), and distortion-product otoacoustic emission (DPOAE) testing.
- To assess hearing changes in MDR-TB patients receiving amikacin.
Main Methods:
- Longitudinal prospective cohort study.
- Included 18-69 year old MDR-TB patients receiving amikacin for the first time.
- Hearing assessed at baseline, 2 months, and 6 months using PTA, HFA, and DPOAE.
Main Results:
- HFA detected hearing shifts at 2 months; PTA detected shifts at 6 months.
- DPOAE testing did not detect significant hearing threshold shifts.
- Sequential analysis refined the final study population to 10 patients.
Conclusions:
- HFA and PTA are effective for detecting amikacin-associated hearing threshold shifts over six months.
- DPOAE testing demonstrated limited efficiency in identifying early ototoxicity in this cohort.
- Monitoring hearing with HFA and PTA is recommended during amikacin treatment for MDR-TB.
Related Concept Videos
Treatment Resistant Cancers
Overview of Microsoft Excel as a Data Analysis Tool
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Resistivity

